Trump Orders FDA Fast-Track of Psychedelics for PTSD Treatment

President Trump signed an executive order directing the Food and Drug Administration to fast-track its review of psychedelic drugs — including psilocybin and ibogaine — as treatments for depression, anxiety, and post-traumatic stress disorder. This marks the first time the federal government has pushed to accelerate approval of any psychedelic compound.

The order directs $50 million in federal funds toward expanding access to psychedelic-assisted therapies. The FDA will issue national priority vouchers to three psychedelics as early as next week, a move that could compress what is typically a years-long review process into a matter of weeks, FDA Commissioner Dr. Marty Makary said.

For the Treasure Coast, where military veterans make up a significant share of the population in Martin, St. Lucie, and Indian River counties, the policy shift carries particular weight. The Department of Veterans Affairs is currently participating in at least five clinical trials of psychedelic therapies — in New York, California, and Oregon — focused specifically on veterans with PTSD. Whether trial sites will expand to Florida remains unclear, but VA-affiliated patients in the region could eventually become eligible for treatments emerging from those trials.

Health and Human Services Secretary Robert F. Kennedy Jr. and Centers for Medicare and Medicaid Services Administrator Dr. Mehmet Oz attended the signing. Also present was former Navy SEAL Marcus Luttrell, whose harrowing account of a deadly Afghanistan mission inspired the film "Lone Survivor." Luttrell addressed Trump directly: "You're going to save a lot of lives through it. It absolutely changed my life for the better."

Podcast host Joe Rogan, also in attendance, said he had texted Trump about ibogaine and the president replied, "Sounds great. Do you want FDA approval? Let's do it."

The order calls for expedited reclassification of psilocybin and ibogaine, both currently listed as Schedule I substances by the Drug Enforcement Administration. That classification designates them as having no accepted medical use and carrying high abuse potential. The designation has long blocked federally funded research. A 2025 study published in the Journal of the American Medical Association found that a single dose of LSD eased anxiety and depression symptoms for months.

Trump cited a sweeping mental health crisis as justification. More than 14 million American adults live with a serious mental illness and approximately eight million are on prescription medication for such conditions, according to the executive order. The National Institute of Mental Health estimates at least 21 million American adults have experienced a major depressive episode.

The FDA rejected approval of MDMA to treat PTSD in 2024. Whether the new fast-track authority will overcome similar scientific and regulatory hurdles for psilocybin and ibogaine should become clearer once the FDA issues its priority vouchers next week.

This article was generated with AI assistance using publicly available information. It was reviewed and approved by a human editor before publication. TC Sentinel uses AI writing tools in accordance with FTC guidelines.